{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006384","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.083659+00:00","generated_at":"2026-06-18T09:49:49.009547+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptevo appoints Lamothe COO, Taylor CFO; base salaries $470K and $404K","bullets":["Jeffrey Lamothe promoted from EVP/CFO to EVP/COO; base salary $470,000, bonus target 45%.","Daphne Taylor promoted from SVP Finance to SVP/CFO; base salary $403,745, bonus target 40%.","Lamothe received 16,500 options and 16,500 RSUs vesting over 3 years under 2018 Stock Plan.","Taylor received 11,000 options and 11,000 RSUs vesting over 3 years; effective March 3, 2023.","No family relationships or reportable transactions involving the appointees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006384","json":"https://secwatch.observer/filing/0000950170-23-006384.json","markdown":"https://secwatch.observer/filing/0000950170-23-006384.md","text":"https://secwatch.observer/filing/0000950170-23-006384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/apvo-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:49:49.009547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25a5de2c82","claim":"Jeffrey G. Lamothe was appointed as Executive Vice President, Chief Operating Officer at Aptevo Therapeutics Inc..","evidence_excerpt":"On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"a9d69c6a63","claim":"Daphne Taylor was appointed as Senior Vice President, Chief Financial Officer at Aptevo Therapeutics Inc..","evidence_excerpt":"Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}